Antiviral Activity against SARS-CoV-2 of Conformationally Constrained Helical Peptides Derived from Angiotensin-Converting Enzyme 2.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Antiviral Activity against SARS-CoV-2 of Conformationally Constrained Helical Peptides Derived from Angiotensin-Converting Enzyme 2.
- Published In:
- ACS omega, 8(25), 22665-22672 (2023)
- Authors:
- Quagliata, Michael, Stincarelli, Maria Alfreda, Papini, Anna Maria(2), Giannecchini, Simone, Rovero, Paolo
- Database ID:
- RPEP-07298
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07298APA
Quagliata, Michael; Stincarelli, Maria Alfreda; Papini, Anna Maria; Giannecchini, Simone; Rovero, Paolo. (2023). Antiviral Activity against SARS-CoV-2 of Conformationally Constrained Helical Peptides Derived from Angiotensin-Converting Enzyme 2.. ACS omega, 8(25), 22665-22672. https://doi.org/10.1021/acsomega.3c01436
MLA
Quagliata, Michael, et al. "Antiviral Activity against SARS-CoV-2 of Conformationally Constrained Helical Peptides Derived from Angiotensin-Converting Enzyme 2.." ACS omega, 2023. https://doi.org/10.1021/acsomega.3c01436
RethinkPeptides
RethinkPeptides Research Database. "Antiviral Activity against SARS-CoV-2 of Conformationally Co..." RPEP-07298. Retrieved from https://rethinkpeptides.com/research/quagliata-2023-antiviral-activity-against-sarscov2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.